ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - tirofiban as hydrochloride monohydrate 0.25 mg/ml - solution for infusion - tirofiban - aggrastat in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy. in this setting, aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - fosaprepitant as fosaprepitant dimeglumine 150 mg - powder for solution for infusion - aprepitant - emend iv 150mg in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - metformin hydrochloride 1000 mg; sitagliptin as monohydrate phosphate 50 mg - tablets - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.